Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Treatment of Recurrent Thyroid Cancer

March 27th 2015

Multidisciplinary Thyroid Cancer Care

March 27th 2015

Radioactive Iodine Treatment for Thyroid Cancer

March 27th 2015

Thyroid Cancer Risk Assessment and Diagnosis

March 27th 2015

Medullary Thyroid Cancer: What is Available?

March 4th 2015

More Personalized Therapy Needed to Improve Survival

March 4th 2015

Current and Future Targets in Thyroid Cancer

March 4th 2015

Key Findings From DECISION and SELECT Trials

March 4th 2015

Monitoring During Active Surveillance and Treatment

March 4th 2015

When to Refer a Patient to a Medical Oncologist

March 4th 2015

Treatments After Progression in DTC

March 4th 2015

Genetic Testing: What Role Do Mutations Play?

March 4th 2015

Interpreting Whole Body Scans

March 4th 2015

Who Are the Best Candidates for TKIs?

March 4th 2015

Approval of Lenvatinib: More Options

March 4th 2015

FDA Grants Rindopepimut Breakthrough Designation for EGFRvIII-Positive Glioblastoma

February 23rd 2015

Rindopepimut (Rintega) has gained a Breakthrough Therapy Designation from the FDA to treat adult patients with glioblastoma multiforme that test positive for the epidermal growth factor receptor variant.

Lenvatinib and Lenalidomide Approved, New Agent Promising in Myeloma, and More

February 20th 2015

Dr. Marcia Brose Discusses Lenvatinib as a New Option in DTC

February 13th 2015

Marcia S. Brose, MD, PhD, associate professor of Otorhinolaryngology: Head and Neck Surgery at the Hospital of the University of Pennsylvania, discusses lenvatinib as a new treatment option for patients with radioactive iodine-refractory differentiated thyroid cancer.

FDA Approves Lenvatinib in Differentiated Thyroid Cancer

February 13th 2015

The FDA has granted approval to lenvatinib (Lenvima) as a treatment for patients with progressive, radioactive iodine-refractory differentiated thyroid cancer.

Sherman Says Lenvatinib Approval "Likely" as FDA Decision Date Nears

February 11th 2015

With a deadline of April 14, the FDA will soon make its final approval decision on the oral multikinase inhibitor lenvatinib as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).